Literature DB >> 15723089

Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis.

Anne-Charlotte de Gouville1, Valerie Boullay, Gael Krysa, Julia Pilot, Jean-Marie Brusq, Florence Loriolle, Jean-Michel Gauthier, Stephen A Papworth, Alain Laroze, Françoise Gellibert, Stephane Huet.   

Abstract

1 Chronic liver disease is characterized by an exacerbated accumulation of matrix, causing progressive fibrosis, which may lead to cirrhosis. Transforming growth factor beta (TGF-beta), a well-known profibrotic cytokine, transduces its signal through the ALK5 ser/thr kinase receptor, and increases transcription of different genes including PAI-1 and collagens. The identification of GW6604 (2-phenyl-4-(3-pyridin-2-yl-1H-pyrazol-4-yl)pyridine), an ALK5 inhibitor, allowed us to evaluate the therapeutic potential of inhibiting TGF-beta pathway in different models of liver disease. 2 A cellular assay was used to identify GW6604 as a TGF-beta signaling pathway inhibitor. This ALK5 inhibitor was then tested in a model of liver hepatectomy in TGF-beta-overexpressing transgenic mice, in an acute model of liver disease and in a chronic model of dimethylnitrosamine (DMN)-induced liver fibrosis. 3 In vitro, GW6604 inhibited autophosphorylation of ALK5 with an IC(50) of 140 nM and in a cellular assay inhibited TGF-beta-induced transcription of PAI-1 (IC(50): 500 nM). In vivo, GW6604 (40 mg kg(-1) p.o.) increased liver regeneration in TGF-beta-overexpressing mice, which had undergone partial hepatectomy. In an acute model of liver disease, GW6604 reduced by 80% the expression of collagen IA1. In a chronic model of DMN-induced fibrosis where DMN was administered for 6 weeks and GW6604 dosed for the last 3 weeks (80 mg kg(-1) p.o., b.i.d.), mortality was prevented and DMN-induced elevations of mRNA encoding for collagen IA1, IA2, III, TIMP-1 and TGF-beta were reduced by 50-75%. Inhibition of matrix genes overexpression was accompanied by reduced matrix deposition and reduction in liver function deterioration, as assessed by bilirubin and liver enzyme levels. 4 Our results suggest that inhibition of ALK5 could be an attractive new approach to treatment of liver fibrotic diseases by both preventing matrix deposition and promoting hepatocyte regeneration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15723089      PMCID: PMC1576127          DOI: 10.1038/sj.bjp.0706172

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  49 in total

Review 1.  Mechanisms of TGF-beta signaling from cell membrane to the nucleus.

Authors:  Yigong Shi; Joan Massagué
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

2.  SIRIUS RED F3BA AS A STAIN FOR CONNECTIVE TISSUE.

Authors:  F SWEAT; H PUCHTLER; S I ROSENTHAL
Journal:  Arch Pathol       Date:  1964-07

3.  Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene.

Authors:  S Dennler; S Itoh; D Vivien; P ten Dijke; S Huet; J M Gauthier
Journal:  EMBO J       Date:  1998-06-01       Impact factor: 11.598

4.  Histologic fixatives suitable for diagnostic light and electron microscopy.

Authors:  E M McDowell; B F Trump
Journal:  Arch Pathol Lab Med       Date:  1976-08       Impact factor: 5.534

5.  Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions.

Authors:  N Sanderson; V Factor; P Nagy; J Kopp; P Kondaiah; L Wakefield; A B Roberts; M B Sporn; S S Thorgeirsson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

Review 6.  Follistatin: a multifunctional regulatory protein.

Authors:  D J Phillips; D M de Kretser
Journal:  Front Neuroendocrinol       Date:  1998-10       Impact factor: 8.606

7.  Histophotometric estimation of volume density of collagen as an indication of fibrosis in rat liver.

Authors:  J James; K S Bosch; F M Zuyderhoudt; J M Houtkooper; J van Gool
Journal:  Histochemistry       Date:  1986

8.  A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections.

Authors:  A López-De León; M Rojkind
Journal:  J Histochem Cytochem       Date:  1985-08       Impact factor: 2.479

9.  Anti-transforming growth factor-beta1 antibody improves survival rate following partial hepatectomy in cirrhotic rats.

Authors:  Kazunori Ohara; Mitsuo Kusano
Journal:  Hepatol Res       Date:  2002-10       Impact factor: 4.288

10.  SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.

Authors:  Gareth J Inman; Francisco J Nicolás; James F Callahan; John D Harling; Laramie M Gaster; Alastair D Reith; Nicholas J Laping; Caroline S Hill
Journal:  Mol Pharmacol       Date:  2002-07       Impact factor: 4.436

View more
  50 in total

1.  Schistosoma japonicum protein SjP40 inhibits TGF-β1-induced activation of hepatic stellate cells.

Authors:  Xiaolei Sun; Lingbo Zhang; Jianxin Wang; Jinling Chen; Dandan Zhu; Pei Shen; Xue He; Jing Pan; Wenxia Peng; Yinong Duan
Journal:  Parasitol Res       Date:  2015-08-14       Impact factor: 2.289

2.  PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells.

Authors:  Caiyan Zhao; Wei Chen; Liu Yang; Lihong Chen; Stephen A Stimpson; Anna Mae Diehl
Journal:  Biochem Biophys Res Commun       Date:  2006-09-22       Impact factor: 3.575

3.  Molecular characterization of a precision-cut rat liver slice model for the evaluation of antifibrotic compounds.

Authors:  Xinqiang Huang; Hong Cai; Ron Ammar; Yan Zhang; Yihe Wang; Kandasamy Ravi; John Thompson; Gabor Jarai
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-11-08       Impact factor: 4.052

4.  Structural basis for specificity of TGFβ family receptor small molecule inhibitors.

Authors:  Abiodun A Ogunjimi; Elton Zeqiraj; Derek F Ceccarelli; Frank Sicheri; Jeffrey L Wrana; Laurent David
Journal:  Cell Signal       Date:  2011-10-01       Impact factor: 4.315

5.  GFAP promoter-driven RNA interference on TGF-β1 to treat liver fibrosis.

Authors:  Ningning Yang; Ram I Mahato
Journal:  Pharm Res       Date:  2011-02-23       Impact factor: 4.200

Review 6.  Molecular and cellular mechanisms of liver fibrosis and its regression.

Authors:  Tatiana Kisseleva; David Brenner
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-10-30       Impact factor: 46.802

7.  Discovery of 4-Azaindole Inhibitors of TGFβRI as Immuno-oncology Agents.

Authors:  Yong Zhang; Yufen Zhao; Andrew J Tebben; Steven Sheriff; Max Ruzanov; Mark P Fereshteh; Yi Fan; Jonathan Lippy; Jesse Swanson; Ching-Ping Ho; Barri S Wautlet; Anne Rose; Karen Parrish; Zheng Yang; Andrew F Donnell; Liping Zhang; Brian E Fink; Gregory D Vite; Karen Augustine-Rauch; Joseph Fargnoli; Robert M Borzilleri
Journal:  ACS Med Chem Lett       Date:  2018-10-17       Impact factor: 4.345

8.  EW-7197 inhibits hepatic, renal, and pulmonary fibrosis by blocking TGF-β/Smad and ROS signaling.

Authors:  Sang-A Park; Min-Jin Kim; So-Yeon Park; Jung-Shin Kim; Seon-Joo Lee; Hyun Ae Woo; Dae-Kee Kim; Jeong-Seok Nam; Yhun Yhong Sheen
Journal:  Cell Mol Life Sci       Date:  2014-12-09       Impact factor: 9.261

9.  Activation of protein serine/threonine phosphatase PP2Cα efficiently prevents liver fibrosis.

Authors:  Lirui Wang; Xu Wang; Jing Chen; Zhengyi Yang; Liang Yu; Lihong Hu; Xu Shen
Journal:  PLoS One       Date:  2010-12-06       Impact factor: 3.240

10.  TGF-beta1 gene silencing for treating liver fibrosis.

Authors:  Kun Cheng; Ningning Yang; Ram I Mahato
Journal:  Mol Pharm       Date:  2009 May-Jun       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.